The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
DexCom's over-the-counter continuous glucose monitor, Stelo, has received FDA clearance for pediatric use in children aged 2 years and older. This strategic expansion allows children who do not use insulin to access real-time glucose monitoring through the Stelo biosensor. The approval, finalized in mid-June, broadens the market reach for DexCom’s non-prescription glucose monitoring technology.